Search Results

You are looking at 91 - 100 of 171 items for :

  • "Cervical cancer" x
Clear All
Full access

Daniel Shasha, Pierre Cremieux and Louis Harrison

. Philadelphia, PA : FA Davis Company ; 1996 : 25 . 36 Dusenbery KE McGuire W Holt PJ . Erythropoietin increases hemoglobin during radiation therapy for cervical cancer . Int J Radiat Oncol Biol Phys 1994 ; 29 : 1079 – 1084 . 37 Henke

Full access

John A. Glaspy

in gastric cancer cell growth, angiogenesis, and vessel maturation . J Natl Cancer Inst 2004 ; 96 : 946 – 956 . 20 Dunst J Kuhnt T Strauss HG . Anemia in cervical cancers: impact on survival, patterns of relapse, and association with

Full access

Roy Beveridge, John Fox, Susan A. Higgins, Martin Kohn, John J. Mahoney, Lee N. Newcomer, Andrew von Eschenbach and Clifford Goodman

of Therapeutic Radiology and the Division of Obstetrics and Gynecology at Yale University School of Medicine. “I work in the land of the ‘haves’ and ‘have-nots,’” she explained. “We still see stage IV cervical cancer in our underprivileged patients

Full access

Katherine Cotangco, Mary Meram and M. Patrick Lowe

approved pembrolizumab for the treatment of recurrent or metastatic cervical cancer with PD-L1 expression in 2018. In September 2019, pembrolizumab with lenvatinib was approved as a combined treatment of recurrent or metastatic endometrial cancer in

Full access

and most need for the region. NCCN plans to address additional cancer types in future editions. The delegation from NCCN includes CEO Dr. Carlson, as well as Chief Medical Officer Wui-Jin Koh, MD, former Chair of the NCCN Guidelines Panel for Cervical

Full access

Guidelines for Ovarian Cancer were discussed by Dr. Robert Morgan, Panel Chair and Staff Physician, Department of Medical Oncology, at City of Hope Comprehensive Cancer Center. Dr. Morgan also presented on the NCCN Guidelines for Cervical Cancer. The NCCN

Full access

Linda N. Oseso, Elizabeth Y. Chiao and Rachel A. Bender Ignacio

; Kaposi sarcoma [KS], non-Hodgkin lymphoma [NHL], and cervical cancer) and non–aids-defining cancers (NADCs; all other tumors). HIVAMs are a highly heterogeneous group of diseases with variable linkage to immunosuppression, viral oncogenes, and other risk

Full access

Suneel D. Kamath, Sheetal M. Kircher and Al B. Benson III

.4%), endometrial cancer ($5.4 million; 0.4%), cervical cancer ($5.4 million; 0.4%), MDS ($5.6 million; 0.4%), and liver and bile duct cancers ($5.8 million; 0.4%). Notably, there were no NPOs that had at least $5 million in annual revenue supporting kidney, bladder

Full access

Kshama Jaiswal, Madelyne Hull, Anna L. Furniss, Reina Doyle, Natalia Gayou and Elizabeth Bayliss

reconstruction . JAMA Facial Plast Surg 2014 ; 16 : 55 – 57 . 21. Miller JW Hanson V Johnson GD . From cancer screening to treatment: service delivery and referral in the National Breast and Cervical Cancer Early Detection Program . Cancer 2014

Full access

Alexander P. Cole, Chang Lu, Marieke J. Krimphove, Julie Szymaniak, Maxine Sun, Sean A. Fletcher, Stuart R. Lipsitz, Brandon A. Mahal, Paul L. Nguyen, Toni K. Choueiri, Adam S. Kibel, Adil H. Haider and Quoc-Dien Trinh

cervical cancer. 1 , 8 Regarding long-term outcomes such as mortality, some cancers have been shown to have particularly strong associations between insurance coverage and cancer-specific mortality (CSM). For example, uninsured men with testicular cancer